NEW YORK, NY--(Marketwire -03\/19\/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation out of Washington boosts the sector's reach. The iShares NASDAQ Biotechnology Index (IBB) is currently up more than 16 percent year to date, reflecting an uptick in investor sentiment. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on CEL-SCI Inc. (NASDAQ: CVM - News) & Human Genome Sciences Inc. (NASDAQ: HGSI - News). Access to the full company reports can be found at: <\/p>\n
http:\/\/www.paragonreport.com\/CVM<\/a> <\/p>\n http:\/\/www.paragonreport.com\/HGSI<\/a> <\/p>\n Earlier this month the Biotechnology Industry Organization applauded the Faster Access to Specialized Treatments (FAST) Act. According to BIO the legislation will modernize the Accelerated Approval pathway to expedite the development of modern, targeted, and personalized therapies for patients suffering from serious and life-threatening diseases. <\/p>\n BIO President and CEO Jim Greenwood says the FAST act will speed access to innovative new therapies and cures to patients living with debilitating and life-threatening diseases such as Parkinson's, Alzheimer's, diabetes and numerous rare diseases for which there is currently no treatment or cure. <\/p>\n The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http:\/\/www.paragonreport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n CEL-SCI Inc.'s lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. Earlier this month the company reported that it has fully paid off its outstanding convertible debenture. The Company had been making monthly payments of approximately $1 million per month to repay a $9 million convertible debenture which CEL-SCI had issued in connection with the settlement of litigation. <\/p>\n Human Genome Sciences said it lost $81 million, or 41 cents per share, in the fourth quarter of 2011 compared with a loss of $87.6 million, or 46 cents per share, in 2010's fourth quarter. Revenue more than doubled, to $45.5 million from $21.3 million. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Go here to read the rest: NEW YORK, NY--(Marketwire -03\/19\/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation out of Washington boosts the sector's reach. Continue reading
\nCEL-SCI and Human Genome Sciences Poised to Benefit From Favorable Legislation<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"